Corrigendum to "The race toward a universal influenza vaccine: Front runners and the future directions" [Antivir. Res. (2022) 105505]

Affiliations

¹ State Key Laboratory of Respiratory Diseases, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
² State Key Laboratory of Respiratory Diseases, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China; Guangdong South China Vaccine, Guangzhou, China; Greater Bay Area Innovative Vaccine Technology Development Center, Guangzhou International Bio-island Laboratory, Guangzhou, China. Electronic address: peng_tao@gibh.ac.cn.

Published Erratum

Longbo Hu et al. Antiviral Res. 2023 Mar.

. 2023 Mar:211:105543.

doi: 10.1016/j.antiviral.2023.105543. Epub 2023 Jan 15.

¹ State Key Laboratory of Respiratory Diseases, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
² State Key Laboratory of Respiratory Diseases, Sino-French Hoffmann Institute, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China; Guangdong South China Vaccine, Guangzhou, China; Greater Bay Area Innovative Vaccine Technology Development Center, Guangzhou International Bio-island Laboratory, Guangzhou, China. Electronic address: peng_tao@gibh.ac.cn.

No abstract available

Erratum for

The race toward a universal influenza vaccine: Front runners and the future directions.
Hu L, Lao G, Liu R, Feng J, Long F, Peng T. Hu L, et al. Antiviral Res. 2023 Feb;210:105505. doi: 10.1016/j.antiviral.2022.105505. Epub 2022 Dec 24. Antiviral Res. 2023. PMID: 36574905 Review.